The present invention provides a tumor blood marker and a use thereof. Specifically, the present invention provides a use of a reagent, which is used to detect GAPDH in a blood sample, in a preparation of a detecting composition for tumor screening, risk evaluation of tumor development in subjects, distinction of tumor progression stages, identification of therapeutic efficacy of tumor and/or risk analysis of tumor progression. The present invention also provides a kit and a method for detecting GAPDH concentrations in blood samples.

A yeast comprising a nucleotide sequence expression system expressing a synthetic Calvin cycle comprising heterologous genes, which include at least a) a gene encoding an enzyme from the class of the ribulose-bisphosphate carboxylases (EC number: 4.1.1.39) (RuBisCO gene); and b) a gene encoding an enzyme from the class of the ribulose phosphate kinases (EC number: 2.7.1.19) (PRK gene), which is expressing; wherein the yeast optionally comprises a heterologous expression construct expressing a gene of interest (GOI) and/or wherein each of said RuBisCO gene and said PRK gene, is fused with a nucleotide sequence encoding a peroxisomal targeting signal (PTS).

Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.

Lateral flow devices, methods and kits for performing lateral flow western blot assays are provided.

Provided herein, in some embodiments, are compositions and methods for a plasmid addiction system based on essential glycolytic genes. Also provided herein, in some embodiments, are compositions and methods for a plasmid addiction system based on an outer membrane efflux protein.

Provided is a technique for improving the translation efficiency of mRNA. The mRNA includes: a 5 untranslated region of an mRNA encoding a protein; and a 3 untranslated region having 40% or more and 80% or less complementarity to the 5 untranslated region.

Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.

The disclosure relates to host cells having altered NADPH availability, allowing for increased production of compounds produced using NADPH, and methods of use thereof. NADPH availability is altered by one or more of: expressing an altered GAPDH, expressing a variant glutamate dehydrogenase (gdh), aspartate semialdehyde dehydrogenase (asd), dihydropicolinate reductase (dapB), and meso-diaminopimelate dehydrogenase (ddh), expressing a novel nicotinamide nucleotide transhydrogenase, expressing a novel threonine aldolase, and expressing or modulating the expression of a pyruvate carboxylase in the host cells.

The present invention provides a tumor blood marker and a use thereof. Specifically, the present invention provides a use of a reagent, which is used to detect GAPDH in a blood sample, in a preparation of a detecting composition for tumor screening, risk evaluation of tumor development in subjects, distinction of tumor progression stages, identification of therapeutic efficacy of tumor and/or risk analysis of tumor progression. The present invention also provides a kit and a method for detecting GAPDH concentrations in blood samples.

Provided herein are genetically engineered mammalian (e.g., human) cells that express one or more transgenes at a sustained expression level. Also provided are methods of making and using the cells.